Are you over 18 and want to see adult content?
More Annotations

A complete backup of www.voltageorgasm.com
Are you over 18 and want to see adult content?

A complete backup of www.xtreamporn.com
Are you over 18 and want to see adult content?

A complete backup of www.pussygranny.com
Are you over 18 and want to see adult content?

A complete backup of www.yesbitch.net
Are you over 18 and want to see adult content?

A complete backup of www.sexsexvideo.com
Are you over 18 and want to see adult content?

A complete backup of www.freeomovie.info
Are you over 18 and want to see adult content?

A complete backup of www.pillaporno.com
Are you over 18 and want to see adult content?

A complete backup of besthugecocks.com
Are you over 18 and want to see adult content?
Favourite Annotations

БеÑÐ¿Ð»Ð°Ñ‚Ð½Ð°Ñ ÑŽÑ€Ð¸Ð´Ð¸Ñ‡ÐµÑÐºÐ°Ñ ÐºÐ¾Ð½ÑÑƒÐ»ÑŒÑ‚Ð°Ñ†Ð¸Ñ Ð¾Ð½Ð»Ð°Ð¹Ð½ - Мое Право
Are you over 18 and want to see adult content?

Bienvenidos a la revista El Notario del Siglo XXI
Are you over 18 and want to see adult content?

2020 Free Practice Exam Collection - FreeCram.com
Are you over 18 and want to see adult content?

ARGIA Kazetaritza independentea. Txikitik eragiten
Are you over 18 and want to see adult content?

æ¿€ãƒãƒƒã‚¯(Gekirock) - ラウドãƒãƒƒã‚¯ãƒ»ãƒãƒ¼ã‚¿ãƒ«
Are you over 18 and want to see adult content?

Porsche Parts and Accessories - Vertex Auto
Are you over 18 and want to see adult content?

TTSReader - Text To Speech Reader. Online, Free & Unlimited
Are you over 18 and want to see adult content?
Text
ADVANCED WOUND CARE
The MolecuLight i:X Wound Imaging Device allows clinicians to quickly, safely, and easily visualize bacteria 2 and measure wounds 7 at the point of care, so they have maximum insights for accurate treatment selection and accelerated healing. CASE STUDY. WOUND ASSESSMENT TOOL The use of the MolecuLight i:X in managing burns: a pilot study. Journal of Burn Care & Research, 2017, 39 (1), 154-161. doi: 10.1097/BCR.0000000000000565. Raizman R. Fluorescence imaging positively predicts bacterial presence and guides wound cleaning and patient education in a series of pilonidal sinus patients. Presentedat Wounds UK 2016.
CLINICAL IMAGE GALLERY OF FLUORESCENCE IMAGES Clinical Image Gallery of Fluorescence Images. Below are a series of images/videos highlighting how the MolecuLight i:X helped clinicians detect fluorescent bacteria and measure wounds to facilitate evidence-based clinician decision making. Search for:PRESS RELEASES
Press Release: MolecuLight receives $990,000 from FedDev Ontario to complete commercialization of a new clinical wound imaging technology. November 7, 2014 — PRESS RELEASE. Press Release: MolecuLight announces research collaborationVISUALIZE BACTERIA
The MolecuLight i:X is a handheld fluorescence imaging device that provides instant visual detection and documentation of potentially harmful bacteria in wounds that would otherwise be invisible. 1 The MolecuLight i:X emits a precise wavelength of safe violet light, which interacts with the wound tissue and bacteria causing the wound and MOLECULIGHT DARKDRAPE The MolecuLight DarkDrape is a one-time use consumable that easily connects to the MolecuLight i:X with a built-in adapter. The DarkDrape is made of flexible polyethylene material that contours around any body part while the built-in adapter features a support frame to maintain an unobstructed field of view, enabling fast and easy imagingof
A PROSPECTIVE MULTISITE OBSERVATIONAL STUDY INCORPORATING ABSTRACT Introduction. The UPPER/LOWER infection checklists look for signs and symptoms of local/superficial infection (UPPER) and deep infection (LOWER) to assist clinicians in identifying and distinguishing between these infection levels, facilitating appropriate treatment. The presence of 3 or more UPPER or LOWER criteria is indicative of infection. Objective. This study evaluatedthe
MOELLEKEN M ET AL. INTERNATIONAL WOUND JOURNAL (2020) Continued >> Illuminating the Evidence Publication Summary Prospective clinical study on the efficacy of bacterial removal with mechanical debridement in and aroundADVANCED WOUND CARE
Intended Use & Indication for Use. The MolecuLight i:X is intended for use as a handheld imaging tool that allows clinicians diagnosing and treating skin wounds, at the point of care, to: (iii) View and digitally record images of fluorescence emitted from a wound when exposed to an excitation light. REIMBURSEMENT PATHWAY FOR FLUORESCENCE IMAGING AND Reimbursement Pathway for Fluorescence Imaging and Detection of Wounds Containing Bacterial Burden (>104 CFU/g)* * when used in combination with clinical signs and symptoms There are CPT codes and an APC assignment specific to the procedure for “fluorescence wound imaging for bacterial presence, location, and load”1,2. The MolecuLight i:X® is the only fluorescence imaging deviceADVANCED WOUND CARE
The MolecuLight i:X Wound Imaging Device allows clinicians to quickly, safely, and easily visualize bacteria 2 and measure wounds 7 at the point of care, so they have maximum insights for accurate treatment selection and accelerated healing. CASE STUDY. WOUND ASSESSMENT TOOL The use of the MolecuLight i:X in managing burns: a pilot study. Journal of Burn Care & Research, 2017, 39 (1), 154-161. doi: 10.1097/BCR.0000000000000565. Raizman R. Fluorescence imaging positively predicts bacterial presence and guides wound cleaning and patient education in a series of pilonidal sinus patients. Presentedat Wounds UK 2016.
CLINICAL IMAGE GALLERY OF FLUORESCENCE IMAGES Clinical Image Gallery of Fluorescence Images. Below are a series of images/videos highlighting how the MolecuLight i:X helped clinicians detect fluorescent bacteria and measure wounds to facilitate evidence-based clinician decision making. Search for:PRESS RELEASES
Press Release: MolecuLight receives $990,000 from FedDev Ontario to complete commercialization of a new clinical wound imaging technology. November 7, 2014 — PRESS RELEASE. Press Release: MolecuLight announces research collaborationVISUALIZE BACTERIA
The MolecuLight i:X is a handheld fluorescence imaging device that provides instant visual detection and documentation of potentially harmful bacteria in wounds that would otherwise be invisible. 1 The MolecuLight i:X emits a precise wavelength of safe violet light, which interacts with the wound tissue and bacteria causing the wound and MOLECULIGHT DARKDRAPE The MolecuLight DarkDrape is a one-time use consumable that easily connects to the MolecuLight i:X with a built-in adapter. The DarkDrape is made of flexible polyethylene material that contours around any body part while the built-in adapter features a support frame to maintain an unobstructed field of view, enabling fast and easy imagingof
A PROSPECTIVE MULTISITE OBSERVATIONAL STUDY INCORPORATING ABSTRACT Introduction. The UPPER/LOWER infection checklists look for signs and symptoms of local/superficial infection (UPPER) and deep infection (LOWER) to assist clinicians in identifying and distinguishing between these infection levels, facilitating appropriate treatment. The presence of 3 or more UPPER or LOWER criteria is indicative of infection. Objective. This study evaluatedthe
MOELLEKEN M ET AL. INTERNATIONAL WOUND JOURNAL (2020) Continued >> Illuminating the Evidence Publication Summary Prospective clinical study on the efficacy of bacterial removal with mechanical debridement in and aroundADVANCED WOUND CARE
Intended Use & Indication for Use. The MolecuLight i:X is intended for use as a handheld imaging tool that allows clinicians diagnosing and treating skin wounds, at the point of care, to: (iii) View and digitally record images of fluorescence emitted from a wound when exposed to an excitation light. REIMBURSEMENT PATHWAY FOR FLUORESCENCE IMAGING AND Reimbursement Pathway for Fluorescence Imaging and Detection of Wounds Containing Bacterial Burden (>104 CFU/g)* * when used in combination with clinical signs and symptoms There are CPT codes and an APC assignment specific to the procedure for “fluorescence wound imaging for bacterial presence, location, and load”1,2. The MolecuLight i:X® is the only fluorescence imaging devicePRESS RELEASES
Press Release: MolecuLight receives $990,000 from FedDev Ontario to complete commercialization of a new clinical wound imaging technology. November 7, 2014 — PRESS RELEASE. Press Release: MolecuLight announces research collaboration WHAT IS THE MOLECULIGHT I:X PROCEDURE? What is the MolecuLight i:X procedure? This 7-minute presentation will cover: How the MolecuLight i:X works. Detecting wounds with elevated bacterial loads. What the wound care clinical workflow looks like with the MolecuLight i:X. Typical cost savings. Reimbursement for the fluorescence imaging procedure. Fluorescence imaging & woundmeasurement.
I:X® TELEMEDICINE SOLUTION The use of telemedicine is rapidly increasing in wound care. However, traditional signs and symptoms of infection can be difficult to determine remotely. Access to expert wound care practitioners at the bedside can be increasingly limited, especially in long term care facilities and homecare clinics, or when travel by specialists is challenging, such as in MOLECULIGHT EXECUTIVE TEAM MolecuLight Inc. is a privately owned, Canadian medical imaging company founded by Dr. Ralph DaCosta and incorporated on June 1, 2012. The company’s first product, the MolecuLight i:X, is a first-of-its kind handheld imaging device based on Dr. DaCosta’s invention. MolecuLight is based in Toronto, Canada. MOLECULIGHT ANNOUNCES CMS HAS ASSIGNED AN APC New Code Enables Reimbursement to Hospital Outpatient Centers Using MolecuLight i:X Toronto, CANADA – (June 11, 2020) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of bacteria in wounds, announces that the Centers for Medicare & Medicaid Services (CMS) has assigned an Ambulatory Payment Classification (APC) code 5722 for the MolecuLight FREQUENTLY ASKED QUESTIONS (FAQ) In a darkened room, or using a DarkDrape™, the MolecuLight i:X shines a safe violet excitation light (405 nm) on a wound. This causes wound components (skin, slough, blood, bacteria, etc.) to fluoresce (or emit light) in different colours 1–4 .The i:X device displays and captures images of the most informative of these fluorescentcolours.
UTILITY OF MOLECULIGHT FOR WOUND CARE PATIENTS The MolecuLight i:X is a hand-held imaging device that uses a safe violet light to help wound care professionals detect bacteria in your wound and to measure the size of your wound.. The MolecuLight i:X captures both images and videos that can be saved with your medical records to track how your wound is healing. Taking images with the MolecuLight i:X gives your wound care provider information COST-SAVINGS/ REIMBURSEMENT F luorescence imaging was more accurate than clinical judgement in detecting elevated bacterial loads. $ 7,660 USD per patient was the estimated cost savings from using fluorescence imaging information. T his information avoided the application of cellular tissue products on wounds with high levels of bacteria. MOLECULIGHT I:X QUICK START GUIDE a. Ensurei:X is OFF or turn device OFF and Display Screen OFF. b. Use a disinfecting wipe to preclean the i:X. d. Use lens towelette to clean all glass surfaces. e. Check that all windows areADVANCED WOUND CARE
1 American Diabetes Society, Diagnosis and Management of Diabetic Foot Infections, 2020 2 Heather L. Orsted et al., Foundations of Best Practice for Skin and Wound Management Skin: Anatomy, Physiology and Wound Healing 3 Robson MC et al., Guidelines for the treatment of venous ulcers. Wound Repair Regen. 2006 Nov-Dec;14(6):649-62 4 Emily Haesler et al., National Pressure Ulcer Advisory PanelADVANCED WOUND CARE
The MolecuLight i:X Wound Imaging Device allows clinicians to quickly, safely, and easily visualize bacteria 2 and measure wounds 7 at the point of care, so they have maximum insights for accurate treatment selection and accelerated healing. CASE STUDY. WOUND ASSESSMENT TOOL The use of the MolecuLight i:X in managing burns: a pilot study. Journal of Burn Care & Research, 2017, 39 (1), 154-161. doi: 10.1097/BCR.0000000000000565. Raizman R. Fluorescence imaging positively predicts bacterial presence and guides wound cleaning and patient education in a series of pilonidal sinus patients. Presentedat Wounds UK 2016.
CLINICAL IMAGE GALLERY OF FLUORESCENCE IMAGES Clinical Image Gallery of Fluorescence Images. Below are a series of images/videos highlighting how the MolecuLight i:X helped clinicians detect fluorescent bacteria and measure wounds to facilitate evidence-based clinician decision making. Search for:VISUALIZE BACTERIA
The MolecuLight i:X is a handheld fluorescence imaging device that provides instant visual detection and documentation of potentially harmful bacteria in wounds that would otherwise be invisible. 1 The MolecuLight i:X emits a precise wavelength of safe violet light, which interacts with the wound tissue and bacteria causing the wound and MOLECULIGHT ANNOUNCES CMS HAS ASSIGNED AN APC New Code Enables Reimbursement to Hospital Outpatient Centers Using MolecuLight i:X Toronto, CANADA – (June 11, 2020) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of bacteria in wounds, announces that the Centers for Medicare & Medicaid Services (CMS) has assigned an Ambulatory Payment Classification (APC) code 5722 for the MolecuLight i:XWOUNDSOURCE WEBINAR
The MolecuLight i:X for point-of-care detection of elevated bacterial burden in wounds – in real-time A PROSPECTIVE MULTISITE OBSERVATIONAL STUDY INCORPORATING ABSTRACT Introduction. The UPPER/LOWER infection checklists look for signs and symptoms of local/superficial infection (UPPER) and deep infection (LOWER) to assist clinicians in identifying and distinguishing between these infection levels, facilitating appropriate treatment. The presence of 3 or more UPPER or LOWER criteria is indicative of infection. Objective. This study evaluatedthe
POINT OF CARE IDENTIFICATION Point of Care Identification of. Pseudomonas Aeruginosa. Case Study. Pseudomonas aeruginosa is one of the most common pathogens found in chronic leg ulcers. 1 It frequently leads to stalled wound healing and its unique intrinsic and acquired antibiotic resistances make early identification and selection of Pseudomonas -specific treatmentADVANCED WOUND CARE
Intended Use & Indication for Use. The MolecuLight i:X is intended for use as a handheld imaging tool that allows clinicians diagnosing and treating skin wounds, at the point of care, to: (iii) View and digitally record images of fluorescence emitted from a wound when exposed to an excitation light. MOLECULIGHT I:X QUICK START GUIDE a. Ensurei:X is OFF or turn device OFF and Display Screen OFF. b. Use a disinfecting wipe to preclean the i:X. d. Use lens towelette to clean all glass surfaces. e. Check that all windows areADVANCED WOUND CARE
The MolecuLight i:X Wound Imaging Device allows clinicians to quickly, safely, and easily visualize bacteria 2 and measure wounds 7 at the point of care, so they have maximum insights for accurate treatment selection and accelerated healing. CASE STUDY. WOUND ASSESSMENT TOOL The use of the MolecuLight i:X in managing burns: a pilot study. Journal of Burn Care & Research, 2017, 39 (1), 154-161. doi: 10.1097/BCR.0000000000000565. Raizman R. Fluorescence imaging positively predicts bacterial presence and guides wound cleaning and patient education in a series of pilonidal sinus patients. Presentedat Wounds UK 2016.
CLINICAL IMAGE GALLERY OF FLUORESCENCE IMAGES Clinical Image Gallery of Fluorescence Images. Below are a series of images/videos highlighting how the MolecuLight i:X helped clinicians detect fluorescent bacteria and measure wounds to facilitate evidence-based clinician decision making. Search for:VISUALIZE BACTERIA
The MolecuLight i:X is a handheld fluorescence imaging device that provides instant visual detection and documentation of potentially harmful bacteria in wounds that would otherwise be invisible. 1 The MolecuLight i:X emits a precise wavelength of safe violet light, which interacts with the wound tissue and bacteria causing the wound and MOLECULIGHT ANNOUNCES CMS HAS ASSIGNED AN APC New Code Enables Reimbursement to Hospital Outpatient Centers Using MolecuLight i:X Toronto, CANADA – (June 11, 2020) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of bacteria in wounds, announces that the Centers for Medicare & Medicaid Services (CMS) has assigned an Ambulatory Payment Classification (APC) code 5722 for the MolecuLight i:XWOUNDSOURCE WEBINAR
The MolecuLight i:X for point-of-care detection of elevated bacterial burden in wounds – in real-time A PROSPECTIVE MULTISITE OBSERVATIONAL STUDY INCORPORATING ABSTRACT Introduction. The UPPER/LOWER infection checklists look for signs and symptoms of local/superficial infection (UPPER) and deep infection (LOWER) to assist clinicians in identifying and distinguishing between these infection levels, facilitating appropriate treatment. The presence of 3 or more UPPER or LOWER criteria is indicative of infection. Objective. This study evaluatedthe
POINT OF CARE IDENTIFICATION Point of Care Identification of. Pseudomonas Aeruginosa. Case Study. Pseudomonas aeruginosa is one of the most common pathogens found in chronic leg ulcers. 1 It frequently leads to stalled wound healing and its unique intrinsic and acquired antibiotic resistances make early identification and selection of Pseudomonas -specific treatmentADVANCED WOUND CARE
Intended Use & Indication for Use. The MolecuLight i:X is intended for use as a handheld imaging tool that allows clinicians diagnosing and treating skin wounds, at the point of care, to: (iii) View and digitally record images of fluorescence emitted from a wound when exposed to an excitation light. MOLECULIGHT I:X QUICK START GUIDE a. Ensurei:X is OFF or turn device OFF and Display Screen OFF. b. Use a disinfecting wipe to preclean the i:X. d. Use lens towelette to clean all glass surfaces. e. Check that all windows are WHAT IS THE MOLECULIGHT I:X PROCEDURE? What is the MolecuLight i:X procedure? This 7-minute presentation will cover: How the MolecuLight i:X works. Detecting wounds with elevated bacterial loads. What the wound care clinical workflow looks like with the MolecuLight i:X. Typical cost savings. Reimbursement for the fluorescence imaging procedure. Fluorescence imaging & woundmeasurement.
MOLECULIGHT EXECUTIVE TEAM MolecuLight Inc. is a privately owned, Canadian medical imaging company founded by Dr. Ralph DaCosta and incorporated on June 1, 2012. The company’s first product, the MolecuLight i:X, is a first-of-its kind handheld imaging device based on Dr. DaCosta’s invention. MolecuLight is based in Toronto, Canada. FREQUENTLY ASKED QUESTIONS (FAQ) In a darkened room, or using a DarkDrape™, the MolecuLight i:X shines a safe violet excitation light (405 nm) on a wound. This causes wound components (skin, slough, blood, bacteria, etc.) to fluoresce (or emit light) in different colours 1–4 .The i:X device displays and captures images of the most informative of these fluorescentcolours.
NOVEL TECHNOLOGY TO HELP IMPROVE WOUND CARE IN CANADA Results of Clinical Integration Project of MolecuLight i:X® Point-of-Care Imaging Device Illustrate Improved Access, Effectiveness and Efficiency of Wound Care TORONTO, Ontario – (May 18, 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for detection of wounds containing elevated bacterial loads, is helping to improve wound care in Canada with the only point-ofWOUNDSOURCE WEBINAR
The MolecuLight i:X for point-of-care detection of elevated bacterial burden in wounds – in real-time MOLECULIGHT RECEIVES FDA 510K CLEARANCE FOR I:X FDA Approval Extends Label to Include MolecuLight i:X Wound Care Device Features TORONTO, Canada – (December 5, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization of fluorescence in wounds, has received FDA 510(k) clearance for its i:X® handheld fluorescence imaging device for use in the detection of wounds containing bacteria. UTILITY OF MOLECULIGHT FOR WOUND CARE PATIENTS The MolecuLight i:X is a hand-held imaging device that uses a safe violet light to help wound care professionals detect bacteria in your wound and to measure the size of your wound.. The MolecuLight i:X captures both images and videos that can be saved with your medical records to track how your wound is healing. Taking images with the MolecuLight i:X gives your wound care provider information MOLECULIGHT I:XTM USER MANUAL MolecuLight i:XTM User Manual Revision 1.0 Page 6 of 43 Warning The MolecuLight i:X Imaging Device comes fully assembled and ready for use. No modification of this equipment is allowed. Modification of the device will void the terms of the warranty. WOUND HEALING: WHAT IS THE NICE GUIDANCE FROM THE UK Abstract Alteration of wound healing increases the risk of a patient’s morbidity and mortality. This can lead to scarring, infection, malignant transformation and a reduction in quality of life. Management of wounds costs the UK an estimated £5.3 billion annually which is paid for by the state, with further financial burden due to health relatedWOUNDSOURCE WEBINAR
View details on the Reimbursement Pathway for the MolecuLight procedure, as well as CME Resources, Training & Education support andClinical Research.
ADVANCED WOUND CARE
The MolecuLight i:X Wound Imaging Device allows clinicians to quickly, safely, and easily visualize bacteria 2 and measure wounds 7 at the point of care, so they have maximum insights for accurate treatment selection and accelerated healing. CASE STUDY. WOUND ASSESSMENT TOOL The use of the MolecuLight i:X in managing burns: a pilot study. Journal of Burn Care & Research, 2017, 39 (1), 154-161. doi: 10.1097/BCR.0000000000000565. Raizman R. Fluorescence imaging positively predicts bacterial presence and guides wound cleaning and patient education in a series of pilonidal sinus patients. Presentedat Wounds UK 2016.
CLINICAL IMAGE GALLERY OF FLUORESCENCE IMAGES Clinical Image Gallery of Fluorescence Images. Below are a series of images/videos highlighting how the MolecuLight i:X helped clinicians detect fluorescent bacteria and measure wounds to facilitate evidence-based clinician decision making. Search for:VISUALIZE BACTERIA
The MolecuLight i:X is a handheld fluorescence imaging device that provides instant visual detection and documentation of potentially harmful bacteria in wounds that would otherwise be invisible. 1 The MolecuLight i:X emits a precise wavelength of safe violet light, which interacts with the wound tissue and bacteria causing the wound andWOUNDSOURCE WEBINAR
The MolecuLight i:X for point-of-care detection of elevated bacterial burden in wounds – in real-time MOLECULIGHT ANNOUNCES CMS HAS ASSIGNED AN APC New Code Enables Reimbursement to Hospital Outpatient Centers Using MolecuLight i:X Toronto, CANADA – (June 11, 2020) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of bacteria in wounds, announces that the Centers for Medicare & Medicaid Services (CMS) has assigned an Ambulatory Payment Classification (APC) code 5722 for the MolecuLight i:X A PROSPECTIVE MULTISITE OBSERVATIONAL STUDY INCORPORATING ABSTRACT Introduction. The UPPER/LOWER infection checklists look for signs and symptoms of local/superficial infection (UPPER) and deep infection (LOWER) to assist clinicians in identifying and distinguishing between these infection levels, facilitating appropriate treatment. The presence of 3 or more UPPER or LOWER criteria is indicative of infection. Objective. This study evaluatedthe
POINT OF CARE IDENTIFICATION Point of Care Identification of. Pseudomonas Aeruginosa. Case Study. Pseudomonas aeruginosa is one of the most common pathogens found in chronic leg ulcers. 1 It frequently leads to stalled wound healing and its unique intrinsic and acquired antibiotic resistances make early identification and selection of Pseudomonas -specific treatmentADVANCED WOUND CARE
Intended Use & Indication for Use. The MolecuLight i:X is intended for use as a handheld imaging tool that allows clinicians diagnosing and treating skin wounds, at the point of care, to: (iii) View and digitally record images of fluorescence emitted from a wound when exposed to an excitation light. REIMBURSEMENT PATHWAY FOR FLUORESCENCE IMAGING AND Reimbursement Pathway for Fluorescence Imaging and Detection of Wounds Containing Bacterial Burden (>104 CFU/g)* * when used in combination with clinical signs and symptoms There are CPT codes and an APC assignment specific to the procedure for “fluorescence wound imaging for bacterial presence, location, and load”1,2. The MolecuLight i:X® is the only fluorescence imaging deviceADVANCED WOUND CARE
The MolecuLight i:X Wound Imaging Device allows clinicians to quickly, safely, and easily visualize bacteria 2 and measure wounds 7 at the point of care, so they have maximum insights for accurate treatment selection and accelerated healing. CASE STUDY. WOUND ASSESSMENT TOOL The use of the MolecuLight i:X in managing burns: a pilot study. Journal of Burn Care & Research, 2017, 39 (1), 154-161. doi: 10.1097/BCR.0000000000000565. Raizman R. Fluorescence imaging positively predicts bacterial presence and guides wound cleaning and patient education in a series of pilonidal sinus patients. Presentedat Wounds UK 2016.
CLINICAL IMAGE GALLERY OF FLUORESCENCE IMAGES Clinical Image Gallery of Fluorescence Images. Below are a series of images/videos highlighting how the MolecuLight i:X helped clinicians detect fluorescent bacteria and measure wounds to facilitate evidence-based clinician decision making. Search for:VISUALIZE BACTERIA
The MolecuLight i:X is a handheld fluorescence imaging device that provides instant visual detection and documentation of potentially harmful bacteria in wounds that would otherwise be invisible. 1 The MolecuLight i:X emits a precise wavelength of safe violet light, which interacts with the wound tissue and bacteria causing the wound andWOUNDSOURCE WEBINAR
The MolecuLight i:X for point-of-care detection of elevated bacterial burden in wounds – in real-time MOLECULIGHT ANNOUNCES CMS HAS ASSIGNED AN APC New Code Enables Reimbursement to Hospital Outpatient Centers Using MolecuLight i:X Toronto, CANADA – (June 11, 2020) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of bacteria in wounds, announces that the Centers for Medicare & Medicaid Services (CMS) has assigned an Ambulatory Payment Classification (APC) code 5722 for the MolecuLight i:X A PROSPECTIVE MULTISITE OBSERVATIONAL STUDY INCORPORATING ABSTRACT Introduction. The UPPER/LOWER infection checklists look for signs and symptoms of local/superficial infection (UPPER) and deep infection (LOWER) to assist clinicians in identifying and distinguishing between these infection levels, facilitating appropriate treatment. The presence of 3 or more UPPER or LOWER criteria is indicative of infection. Objective. This study evaluatedthe
POINT OF CARE IDENTIFICATION Point of Care Identification of. Pseudomonas Aeruginosa. Case Study. Pseudomonas aeruginosa is one of the most common pathogens found in chronic leg ulcers. 1 It frequently leads to stalled wound healing and its unique intrinsic and acquired antibiotic resistances make early identification and selection of Pseudomonas -specific treatmentADVANCED WOUND CARE
Intended Use & Indication for Use. The MolecuLight i:X is intended for use as a handheld imaging tool that allows clinicians diagnosing and treating skin wounds, at the point of care, to: (iii) View and digitally record images of fluorescence emitted from a wound when exposed to an excitation light. REIMBURSEMENT PATHWAY FOR FLUORESCENCE IMAGING AND Reimbursement Pathway for Fluorescence Imaging and Detection of Wounds Containing Bacterial Burden (>104 CFU/g)* * when used in combination with clinical signs and symptoms There are CPT codes and an APC assignment specific to the procedure for “fluorescence wound imaging for bacterial presence, location, and load”1,2. The MolecuLight i:X® is the only fluorescence imaging device WHAT IS THE MOLECULIGHT I:X PROCEDURE? What is the MolecuLight i:X procedure? This 7-minute presentation will cover: How the MolecuLight i:X works. Detecting wounds with elevated bacterial loads. What the wound care clinical workflow looks like with the MolecuLight i:X. Typical cost savings. Reimbursement for the fluorescence imaging procedure. Fluorescence imaging & woundmeasurement.
PRESS RELEASES
Press Release: MolecuLight receives $990,000 from FedDev Ontario to complete commercialization of a new clinical wound imaging technology. November 7, 2014 — PRESS RELEASE. Press Release: MolecuLight announces research collaboration MOLECULIGHT EXECUTIVE TEAM MolecuLight Inc. is a privately owned, Canadian medical imaging company founded by Dr. Ralph DaCosta and incorporated on June 1, 2012. The company’s first product, the MolecuLight i:X, is a first-of-its kind handheld imaging device based on Dr. DaCosta’s invention. MolecuLight is based in Toronto, Canada. FREQUENTLY ASKED QUESTIONS (FAQ) In a darkened room, or using a DarkDrape™, the MolecuLight i:X shines a safe violet excitation light (405 nm) on a wound. This causes wound components (skin, slough, blood, bacteria, etc.) to fluoresce (or emit light) in different colours 1–4 .The i:X device displays and captures images of the most informative of these fluorescentcolours.
AMA ISSUES CATEGORY III CPT CODE FOR REAL TIME Reimbursement Pathway Established for MolecuLight’s i:X Procedure in Wound Care TORONTO, Canada – (February 13, 2020) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time detection of bacteria in wounds, announced that the American Medical Association (AMA) has issued two new CPT category lll codes to enable a reimbursement pathway for point-of UTILITY OF MOLECULIGHT FOR WOUND CARE PATIENTS The MolecuLight i:X is a hand-held imaging device that uses a safe violet light to help wound care professionals detect bacteria in your wound and to measure the size of your wound.. The MolecuLight i:X captures both images and videos that can be saved with your medical records to track how your wound is healing. Taking images with the MolecuLight i:X gives your wound care provider information MOLECULIGHT I:X QUICK START GUIDE a. Ensurei:X is OFF or turn device OFF and Display Screen OFF. b. Use a disinfecting wipe to preclean the i:X. d. Use lens towelette to clean all glass surfaces. e. Check that all windows are THE USE OF THE MOLECULIGHT BACTERIAL CAMERA IN THE Fluorescence imaging targets swabbing to region of bioburden Standard Imaging Mode Fluorescence Imaging Mode 85-year-old male suffered deep dermal and full thickness contact burns EXPERT EDUCATIONAL VIDEO SESSIONS Utility of Point-of-Care Fluorescence for Detection of Elevated Bacterial Burden in an Outpatient Wound Care Setting Charles Andersen, MD, FACS, MAPWCA Chief, Vascular/ Endovascular/ Limb Preservation, Surgery Service (Emeritus), Chief Wound Care Service MAMC Medical Director Wound Care Clinic, Madigan Army Medical Center, Tacoma, WA Duration: 15 minutes Talk Overview: Elevated bacterialWOUNDSOURCE WEBINAR
View details on the Reimbursement Pathway for the MolecuLight procedure, as well as CME Resources, Training & Education support andClinical Research.
ADVANCED WOUND CARE
The MolecuLight i:X Wound Imaging Device allows clinicians to quickly, safely, and easily visualize bacteria 2 and measure wounds 7 at the point of care, so they have maximum insights for accurate treatment selection and accelerated healing. CASE STUDY. WOUND ASSESSMENT TOOL The use of the MolecuLight i:X in managing burns: a pilot study. Journal of Burn Care & Research, 2017, 39 (1), 154-161. doi: 10.1097/BCR.0000000000000565. Raizman R. Fluorescence imaging positively predicts bacterial presence and guides wound cleaning and patient education in a series of pilonidal sinus patients. Presentedat Wounds UK 2016.
CLINICAL IMAGE GALLERY OF FLUORESCENCE IMAGES Clinical Image Gallery of Fluorescence Images. Below are a series of images/videos highlighting how the MolecuLight i:X helped clinicians detect fluorescent bacteria and measure wounds to facilitate evidence-based clinician decision making. Search for:VISUALIZE BACTERIA
The MolecuLight i:X is a handheld fluorescence imaging device that provides instant visual detection and documentation of potentially harmful bacteria in wounds that would otherwise be invisible. 1 The MolecuLight i:X emits a precise wavelength of safe violet light, which interacts with the wound tissue and bacteria causing the wound andWOUNDSOURCE WEBINAR
The MolecuLight i:X for point-of-care detection of elevated bacterial burden in wounds – in real-time MOLECULIGHT ANNOUNCES CMS HAS ASSIGNED AN APC New Code Enables Reimbursement to Hospital Outpatient Centers Using MolecuLight i:X Toronto, CANADA – (June 11, 2020) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of bacteria in wounds, announces that the Centers for Medicare & Medicaid Services (CMS) has assigned an Ambulatory Payment Classification (APC) code 5722 for the MolecuLight i:X A PROSPECTIVE MULTISITE OBSERVATIONAL STUDY INCORPORATING ABSTRACT Introduction. The UPPER/LOWER infection checklists look for signs and symptoms of local/superficial infection (UPPER) and deep infection (LOWER) to assist clinicians in identifying and distinguishing between these infection levels, facilitating appropriate treatment. The presence of 3 or more UPPER or LOWER criteria is indicative of infection. Objective. This study evaluatedthe
POINT OF CARE IDENTIFICATION Point of Care Identification of. Pseudomonas Aeruginosa. Case Study. Pseudomonas aeruginosa is one of the most common pathogens found in chronic leg ulcers. 1 It frequently leads to stalled wound healing and its unique intrinsic and acquired antibiotic resistances make early identification and selection of Pseudomonas -specific treatmentADVANCED WOUND CARE
Intended Use & Indication for Use. The MolecuLight i:X is intended for use as a handheld imaging tool that allows clinicians diagnosing and treating skin wounds, at the point of care, to: (iii) View and digitally record images of fluorescence emitted from a wound when exposed to an excitation light. REIMBURSEMENT PATHWAY FOR FLUORESCENCE IMAGING AND Reimbursement Pathway for Fluorescence Imaging and Detection of Wounds Containing Bacterial Burden (>104 CFU/g)* * when used in combination with clinical signs and symptoms There are CPT codes and an APC assignment specific to the procedure for “fluorescence wound imaging for bacterial presence, location, and load”1,2. The MolecuLight i:X® is the only fluorescence imaging deviceADVANCED WOUND CARE
The MolecuLight i:X Wound Imaging Device allows clinicians to quickly, safely, and easily visualize bacteria 2 and measure wounds 7 at the point of care, so they have maximum insights for accurate treatment selection and accelerated healing. CASE STUDY. WOUND ASSESSMENT TOOL The use of the MolecuLight i:X in managing burns: a pilot study. Journal of Burn Care & Research, 2017, 39 (1), 154-161. doi: 10.1097/BCR.0000000000000565. Raizman R. Fluorescence imaging positively predicts bacterial presence and guides wound cleaning and patient education in a series of pilonidal sinus patients. Presentedat Wounds UK 2016.
CLINICAL IMAGE GALLERY OF FLUORESCENCE IMAGES Clinical Image Gallery of Fluorescence Images. Below are a series of images/videos highlighting how the MolecuLight i:X helped clinicians detect fluorescent bacteria and measure wounds to facilitate evidence-based clinician decision making. Search for:VISUALIZE BACTERIA
The MolecuLight i:X is a handheld fluorescence imaging device that provides instant visual detection and documentation of potentially harmful bacteria in wounds that would otherwise be invisible. 1 The MolecuLight i:X emits a precise wavelength of safe violet light, which interacts with the wound tissue and bacteria causing the wound andWOUNDSOURCE WEBINAR
The MolecuLight i:X for point-of-care detection of elevated bacterial burden in wounds – in real-time MOLECULIGHT ANNOUNCES CMS HAS ASSIGNED AN APC New Code Enables Reimbursement to Hospital Outpatient Centers Using MolecuLight i:X Toronto, CANADA – (June 11, 2020) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of bacteria in wounds, announces that the Centers for Medicare & Medicaid Services (CMS) has assigned an Ambulatory Payment Classification (APC) code 5722 for the MolecuLight i:X A PROSPECTIVE MULTISITE OBSERVATIONAL STUDY INCORPORATING ABSTRACT Introduction. The UPPER/LOWER infection checklists look for signs and symptoms of local/superficial infection (UPPER) and deep infection (LOWER) to assist clinicians in identifying and distinguishing between these infection levels, facilitating appropriate treatment. The presence of 3 or more UPPER or LOWER criteria is indicative of infection. Objective. This study evaluatedthe
POINT OF CARE IDENTIFICATION Point of Care Identification of. Pseudomonas Aeruginosa. Case Study. Pseudomonas aeruginosa is one of the most common pathogens found in chronic leg ulcers. 1 It frequently leads to stalled wound healing and its unique intrinsic and acquired antibiotic resistances make early identification and selection of Pseudomonas -specific treatmentADVANCED WOUND CARE
Intended Use & Indication for Use. The MolecuLight i:X is intended for use as a handheld imaging tool that allows clinicians diagnosing and treating skin wounds, at the point of care, to: (iii) View and digitally record images of fluorescence emitted from a wound when exposed to an excitation light. REIMBURSEMENT PATHWAY FOR FLUORESCENCE IMAGING AND Reimbursement Pathway for Fluorescence Imaging and Detection of Wounds Containing Bacterial Burden (>104 CFU/g)* * when used in combination with clinical signs and symptoms There are CPT codes and an APC assignment specific to the procedure for “fluorescence wound imaging for bacterial presence, location, and load”1,2. The MolecuLight i:X® is the only fluorescence imaging device WHAT IS THE MOLECULIGHT I:X PROCEDURE? What is the MolecuLight i:X procedure? This 7-minute presentation will cover: How the MolecuLight i:X works. Detecting wounds with elevated bacterial loads. What the wound care clinical workflow looks like with the MolecuLight i:X. Typical cost savings. Reimbursement for the fluorescence imaging procedure. Fluorescence imaging & woundmeasurement.
PRESS RELEASES
Press Release: MolecuLight receives $990,000 from FedDev Ontario to complete commercialization of a new clinical wound imaging technology. November 7, 2014 — PRESS RELEASE. Press Release: MolecuLight announces research collaboration MOLECULIGHT EXECUTIVE TEAM MolecuLight Inc. is a privately owned, Canadian medical imaging company founded by Dr. Ralph DaCosta and incorporated on June 1, 2012. The company’s first product, the MolecuLight i:X, is a first-of-its kind handheld imaging device based on Dr. DaCosta’s invention. MolecuLight is based in Toronto, Canada. FREQUENTLY ASKED QUESTIONS (FAQ) In a darkened room, or using a DarkDrape™, the MolecuLight i:X shines a safe violet excitation light (405 nm) on a wound. This causes wound components (skin, slough, blood, bacteria, etc.) to fluoresce (or emit light) in different colours 1–4 .The i:X device displays and captures images of the most informative of these fluorescentcolours.
AMA ISSUES CATEGORY III CPT CODE FOR REAL TIME Reimbursement Pathway Established for MolecuLight’s i:X Procedure in Wound Care TORONTO, Canada – (February 13, 2020) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time detection of bacteria in wounds, announced that the American Medical Association (AMA) has issued two new CPT category lll codes to enable a reimbursement pathway for point-of UTILITY OF MOLECULIGHT FOR WOUND CARE PATIENTS The MolecuLight i:X is a hand-held imaging device that uses a safe violet light to help wound care professionals detect bacteria in your wound and to measure the size of your wound.. The MolecuLight i:X captures both images and videos that can be saved with your medical records to track how your wound is healing. Taking images with the MolecuLight i:X gives your wound care provider information MOLECULIGHT I:X QUICK START GUIDE a. Ensurei:X is OFF or turn device OFF and Display Screen OFF. b. Use a disinfecting wipe to preclean the i:X. d. Use lens towelette to clean all glass surfaces. e. Check that all windows are THE USE OF THE MOLECULIGHT BACTERIAL CAMERA IN THE Fluorescence imaging targets swabbing to region of bioburden Standard Imaging Mode Fluorescence Imaging Mode 85-year-old male suffered deep dermal and full thickness contact burns EXPERT EDUCATIONAL VIDEO SESSIONS Utility of Point-of-Care Fluorescence for Detection of Elevated Bacterial Burden in an Outpatient Wound Care Setting Charles Andersen, MD, FACS, MAPWCA Chief, Vascular/ Endovascular/ Limb Preservation, Surgery Service (Emeritus), Chief Wound Care Service MAMC Medical Director Wound Care Clinic, Madigan Army Medical Center, Tacoma, WA Duration: 15 minutes Talk Overview: Elevated bacterialWOUNDSOURCE WEBINAR
View details on the Reimbursement Pathway for the MolecuLight procedure, as well as CME Resources, Training & Education support andClinical Research.
Cookie Policy
This website uses cookies to enhance your user experience. Learn more DeclineAllow cookies Skip to main content* Wound Care
*
Products
MolecuLight _I:X_
*
Clinical Evidence
Clinical Overview Case Studies PublicationsPosters
Clinical Image Gallery*
Training & Support
Training Resources UserDocumentation FAQ
*
About Us
Executive Team Conferences & Events Press ReleasesCareers
*
Contact Us
*
Request A Demo
*
Request A Demo
Phone: +1 647-362-4684ROW
HOME
WOUND IMAGING DEVICE The first-ever wound assessment device to provide real-time imaging of bacteria distribution at the point of care.Learn More
* 1
MOLECULIGHT _I:__X_ MAY HELP AT EVERY STAGE OF WOUND CARE">
Assessment
Cleaning
Debridement
Sampling
Documentation
Treatment Selection
Antibiotic StewardshipPatient Engagement
ASSESSMENT
Visualize fluorescent bacteria and measure wound surface area in real-time to understand the status of the wound more fully.1,3CLEANING
Allows clinicians to focus cleaning in areas where fluorescent bacteria are located and optimize wound bed preparation.10DEBRIDEMENT
Guides more efficient and targeted debridement.2,6,7SAMPLING
Guides where to sample; 54% more accurate swabbing compared to theLevine technique.3
DOCUMENTATION
Provides objective visual documentation of the presence of fluorescent bacteria and the surface area of the wound.2,9TREATMENT SELECTION
Comparing fluorescent bacteria and wound surface area at each visit may provide real-time objective feedback on impact of treatmentplan.1,2,4
ANTIBIOTIC STEWARDSHIP Supports more responsible antibiotic decision making andselection.6,8,9
PATIENT ENGAGEMENT
Patients easily see and understand why a clinician is taking certain action to clean, debride, and treat a wound in a specific way.4,5ASSESSMENT
Visualize fluorescent bacteria and measure wound surface area in real-time to understand the status of the wound more fully.1,3CLEANING
Allows clinicians to focus cleaning in areas where fluorescent bacteria are located and optimize wound bed preparation.10DEBRIDEMENT
Guides more efficient and targeted debridement.2,6,7SAMPLING
Guides where to sample; 54% more accurate swabbing compared to theLevine technique.3
DOCUMENTATION>
Provides objective visual documentation of the presence of fluorescent bacteria and the surface area of the wound.2,9TREATMENT SELECTION
Comparing fluorescent bacteria and wound surface area at each visit may provide real-time objective feedback on impact of treatmentplan.1,2,4
ANTIBIOTIC STEWARDSHIP Supports more responsible antibiotic decision making andselection.6,8,9
PATIENT ENGAGEMENT
Patients easily see and understand why a clinician is taking certain action to clean, debride, and treat a wound in a specific way.4,5* 1
* 2
* 3
* 4
* 5
* 6
* 7
* 8
Watch Video
MAKING A DIFFERENCE IN WOUND CAREUP TO
50%
MORE ACCURATE SWABBING3Learn More
UP TO
100%
POSITIVE PREDICTIVE VALUE4Learn More
UP TO
9X
FASTER HEALING2
Learn More
PRESS RELEASE
CLINICAL RESULTS FROM THE MOLECULIGHT _I:X_® FLUORESCENCE IMAGING SYSTEM ARE FEATURED IN TWO CLINICAL TALKS AND SEVEN POSTERS AT THE SAWC FALL 2019 ANNUAL CONFERENCE Multiple Trials Illustrate the Significant Clinical Benefit of MolecuLight’s Point-of-Care Fluorescence Imaging Device for ChronicWound Management
LAS VEGAS, USA and TORONTO, Canada – (October 11, 2019) MolecuLight Inc., the world’s leader...Read More
WATCH MOLECULIGHT _I:__X_ IN ACTION The MolecuLight _I:__X_ Wound Imaging Device allows clinicians to quickly, safely, and easily visualize bacteria2 and measure wounds7 at the point of care, so they have maximum insights for accurate treatment selection and accelerated healing.CASE STUDY
REAL-TIME DETECTION OF ASYMPTOMATIC BIOBURDEN WITH THE MOLECULIGHT _I:__X_ REVEALED NEED FOR SYSTEMIC ANTIBIOTICS AND IMMEDIATE HOSPITALIZATION Use of the MolecuLight _I:__X_ to image for bacterial fluorescence, in conjunction with clinical signs & symptoms, adds an additional bacterial-specific piece of information that can be captured and considered in real-time.See Full Case Study
TESTIMONIALS
"The MolecuLight _I:X_ gives clinicians the ability to visualize and therefore target treatment towards clinically undetectable critical colonization. This user friendly point-of-care device is an exciting addition to our wound care protocol." David Russell, MD // Leeds Teaching Hospitals, Leeds, UK "The MolecuLight _I:X_ has transformed my clinical decision making. MolecuLight _I:X_ helps reveal the unexpected and eliminates guesswork."
Rosemary Hill, BSN CWOCN CETN(C) // Vancouver Coastal Health, NorthVancouver, Canada
"The MolecuLight _I:X_ completely changed my decision making and resulted in not only time and cost savings but also improved patientoutcomes.”
Lt Col Steven Jeffery // The Royal Centre for Defence Medicine,Birmingham, UK
"The MolecuLight _I:X_ gives clinicians the ability to visualize and therefore target treatment towards clinically undetectable critical colonization. This user friendly point-of-care device is an exciting addition to our wound care protocol." David Russell, MD // Leeds Teaching Hospitals, Leeds, UK "The MolecuLight _I:X_ has transformed my clinical decision making. MolecuLight _I:X_ helps reveal the unexpected and eliminates guesswork."
Rosemary Hill, BSN CWOCN CETN(C) // Vancouver Coastal Health, NorthVancouver, Canada
"The MolecuLight _I:X_ completely changed my decision making and resulted in not only time and cost savings but also improved patientoutcomes.”
Lt Col Steven Jeffery // The Royal Centre for Defence Medicine,Birmingham, UK
"The MolecuLight _I:X_ gives clinicians the ability to visualize and therefore target treatment towards clinically undetectable critical colonization. This user friendly point-of-care device is an exciting addition to our wound care protocol." David Russell, MD // Leeds Teaching Hospitals, Leeds, UK* 1
* 2
* 3
FIND OUT HOW TO MAKE A DIFFERENCE IN WOUND CARE Request InformationRequest DemoRequest Quote REQUEST MORE INFORMATIONName *
Title
Select one of the following...Mr.Ms.Mrs.Dr.PhDMDProf. Select one of the following...Mr.
Ms.
Mrs.
Dr.
PhD
MD
Prof.
Email Address *
Company/Organization *Phone
Address
City
Province/State *
Country *
Select one of the
following...AfghanistanAlbaniaAlgeriaAndorraAngolaAntigua & BarbudaArgentinaArmeniaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBhutanBoliviaBosnia & HerzegovinaBotswanaBrazilBruneiBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCentral African RepublicChadChileChinaColombiaComorosCongoCongo Democratic RepublicCosta RicaCote d'IvoireCroatiaCubaCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEast TimorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFijiFinlandFranceGabonGambiaGeorgiaGermanyGhanaGreeceGrenadaGuatemalaGuineaGuinea-BissauGuyanaHaitiHondurasHungaryIcelandIndiaIndonesiaIranIraqIrelandIsraelItalyJamaicaJapanJordanKazakhstanKenyaKiribatiKoreaNorthKorea
SouthKosovoKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMauritaniaMauritiusMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMoroccoMozambiqueMyanmar (Burma)NamibiaNauruNepalThe NetherlandsNew ZealandNicaraguaNigerNigeriaNorwayOmanPakistanPalauPalestinian State*PanamaPapua New GuineaParaguayPeruThe PhilippinesPolandPortugalQatarRomaniaRussiaRwandaSt. Kitts & NevisSt. LuciaSt. Vincent & The GrenadinesSamoaSan MarinoSao Tome & PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouthSudanSpainSri
LankaSudanSurinameSwazilandSwedenSwitzerlandSyriaTaiwanTajikistanTanzaniaThailandTogoTongaTrinidad & TobagoTunisiaTurkeyTurkmenistanTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited States of AmericaUruguayUzbekistanVanuatuVatican City (Holy See)VenezuelaVietnamYemenZambiaZimbabwe Select one of the following...Afghanistan
Albania
Algeria
Andorra
Angola
Antigua & Barbuda
Argentina
Armenia
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bhutan
Bolivia
Bosnia & HerzegovinaBotswana
Brazil
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Central African RepublicChad
Chile
China
Colombia
Comoros
Congo
Congo Democratic RepublicCosta Rica
Cote d'Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
East Timor
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Fiji
Finland
France
Gabon
Gambia
Georgia
Germany
Ghana
Greece
Grenada
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
Korea North
Korea South
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Mauritania
Mauritius
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
The Netherlands
New Zealand
Nicaragua
Niger
Nigeria
Norway
Oman
Pakistan
Palau
Palestinian State*
Panama
Papua New Guinea
Paraguay
Peru
The Philippines
Poland
Portugal
Qatar
Romania
Russia
Rwanda
St. Kitts & Nevis
St. Lucia
St. Vincent & The GrenadinesSamoa
San Marino
Sao Tome & Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Tonga
Trinidad & Tobago
Tunisia
Turkey
Turkmenistan
Tuvalu
Uganda
Ukraine
United Arab EmiratesUnited Kingdom
United States of AmericaUruguay
Uzbekistan
Vanuatu
Vatican City (Holy See)Venezuela
Vietnam
Yemen
Zambia
Zimbabwe
Message
I'd like to receive the following: BrochurePublications and PosterseNewsletterOn-Site DemonstrationQuotation* Required fields
REQUEST A DEMO
Thank you your interest in the MolecuLight i:X. Please fill out the form below and we will contact you to set up a demonstration.Name *
Title
Select one of the following...Mr.Ms.Mrs.Dr.PhDMDProf. Select one of the following...Mr.
Ms.
Mrs.
Dr.
PhD
MD
Prof.
Email Address *
Company/Organization *Phone
Address
City
Province/State *
Country *
Select one of the
following...AfghanistanAlbaniaAlgeriaAndorraAngolaAntigua & BarbudaArgentinaArmeniaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBhutanBoliviaBosnia & HerzegovinaBotswanaBrazilBruneiBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCentral African RepublicChadChileChinaColombiaComorosCongoCongo Democratic RepublicCosta RicaCote d'IvoireCroatiaCubaCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEast TimorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFijiFinlandFranceGabonGambiaGeorgiaGermanyGhanaGreeceGrenadaGuatemalaGuineaGuinea-BissauGuyanaHaitiHondurasHungaryIcelandIndiaIndonesiaIranIraqIrelandIsraelItalyJamaicaJapanJordanKazakhstanKenyaKiribatiKoreaNorthKorea
SouthKosovoKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMauritaniaMauritiusMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMoroccoMozambiqueMyanmar (Burma)NamibiaNauruNepalThe NetherlandsNew ZealandNicaraguaNigerNigeriaNorwayOmanPakistanPalauPalestinian State*PanamaPapua New GuineaParaguayPeruThe PhilippinesPolandPortugalQatarRomaniaRussiaRwandaSt. Kitts & NevisSt. LuciaSt. Vincent & The GrenadinesSamoaSan MarinoSao Tome & PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouthSudanSpainSri
LankaSudanSurinameSwazilandSwedenSwitzerlandSyriaTaiwanTajikistanTanzaniaThailandTogoTongaTrinidad & TobagoTunisiaTurkeyTurkmenistanTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited States of AmericaUruguayUzbekistanVanuatuVatican City (Holy See)VenezuelaVietnamYemenZambiaZimbabwe Select one of the following...Afghanistan
Albania
Algeria
Andorra
Angola
Antigua & Barbuda
Argentina
Armenia
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bhutan
Bolivia
Bosnia & HerzegovinaBotswana
Brazil
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Central African RepublicChad
Chile
China
Colombia
Comoros
Congo
Congo Democratic RepublicCosta Rica
Cote d'Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
East Timor
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Fiji
Finland
France
Gabon
Gambia
Georgia
Germany
Ghana
Greece
Grenada
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
Korea North
Korea South
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Mauritania
Mauritius
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
The Netherlands
New Zealand
Nicaragua
Niger
Nigeria
Norway
Oman
Pakistan
Palau
Palestinian State*
Panama
Papua New Guinea
Paraguay
Peru
The Philippines
Poland
Portugal
Qatar
Romania
Russia
Rwanda
St. Kitts & Nevis
St. Lucia
St. Vincent & The GrenadinesSamoa
San Marino
Sao Tome & Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Tonga
Trinidad & Tobago
Tunisia
Turkey
Turkmenistan
Tuvalu
Uganda
Ukraine
United Arab EmiratesUnited Kingdom
United States of AmericaUruguay
Uzbekistan
Vanuatu
Vatican City (Holy See)Venezuela
Vietnam
Yemen
Zambia
Zimbabwe
Message
I would like exclusive access to the latest MolecuLight content.* Required fields
REQUEST QUOTE
Please fill out the form below to request a quotation for the MolecuLight _I:X_ Imaging Device.Name *
Title
Select one of the following...Mr.Ms.Mrs.Dr.PhDMDProf. Select one of the following...Mr.
Ms.
Mrs.
Dr.
PhD
MD
Prof.
Email Address *
Company/Organization *Phone
Address
City
Province/State *
Country *
Select one of the
following...AfghanistanAlbaniaAlgeriaAndorraAngolaAntigua & BarbudaArgentinaArmeniaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBhutanBoliviaBosnia & HerzegovinaBotswanaBrazilBruneiBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCentral African RepublicChadChileChinaColombiaComorosCongoCongo Democratic RepublicCosta RicaCote d'IvoireCroatiaCubaCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEast TimorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFijiFinlandFranceGabonGambiaGeorgiaGermanyGhanaGreeceGrenadaGuatemalaGuineaGuinea-BissauGuyanaHaitiHondurasHungaryIcelandIndiaIndonesiaIranIraqIrelandIsraelItalyJamaicaJapanJordanKazakhstanKenyaKiribatiKoreaNorthKorea
SouthKosovoKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMauritaniaMauritiusMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMoroccoMozambiqueMyanmar (Burma)NamibiaNauruNepalThe NetherlandsNew ZealandNicaraguaNigerNigeriaNorwayOmanPakistanPalauPalestinian State*PanamaPapua New GuineaParaguayPeruThe PhilippinesPolandPortugalQatarRomaniaRussiaRwandaSt. Kitts & NevisSt. LuciaSt. Vincent & The GrenadinesSamoaSan MarinoSao Tome & PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouthSudanSpainSri
LankaSudanSurinameSwazilandSwedenSwitzerlandSyriaTaiwanTajikistanTanzaniaThailandTogoTongaTrinidad & TobagoTunisiaTurkeyTurkmenistanTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited States of AmericaUruguayUzbekistanVanuatuVatican City (Holy See)VenezuelaVietnamYemenZambiaZimbabwe Select one of the following...Afghanistan
Albania
Algeria
Andorra
Angola
Antigua & Barbuda
Argentina
Armenia
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bhutan
Bolivia
Bosnia & HerzegovinaBotswana
Brazil
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Central African RepublicChad
Chile
China
Colombia
Comoros
Congo
Congo Democratic RepublicCosta Rica
Cote d'Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
East Timor
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Fiji
Finland
France
Gabon
Gambia
Georgia
Germany
Ghana
Greece
Grenada
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
Korea North
Korea South
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Mauritania
Mauritius
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
The Netherlands
New Zealand
Nicaragua
Niger
Nigeria
Norway
Oman
Pakistan
Palau
Palestinian State*
Panama
Papua New Guinea
Paraguay
Peru
The Philippines
Poland
Portugal
Qatar
Romania
Russia
Rwanda
St. Kitts & Nevis
St. Lucia
St. Vincent & The GrenadinesSamoa
San Marino
Sao Tome & Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Tonga
Trinidad & Tobago
Tunisia
Turkey
Turkmenistan
Tuvalu
Uganda
Ukraine
United Arab EmiratesUnited Kingdom
United States of AmericaUruguay
Uzbekistan
Vanuatu
Vatican City (Holy See)Venezuela
Vietnam
Yemen
Zambia
Zimbabwe
Message
I would like exclusive access to the latest MolecuLight content.* Required fields
STAY ON TOP OF THE LATEST ADVANCEMENTS IN WOUND CARE Follow us on Follow Uson
UPDATES FROM TWITTER- October 24, 2019
RT @Wound_Guy : “Real time bacterial fluorescence imaging (MolecuLight) facilitated evidence-based deployment of systemic antibiotics and prevented their unnecessary use.” Hill 2018. This is antibiotic stewardship in action. #antibiotics #healthcare #nursing #wounds__
__1
__
- October 24, 2019
RT @PodiatryToday : New DPM Blog by Barbara Aung, DPM: Emerging Insights On The Diagnostic Benefits Of Fluorescence Imaging In Wound Care https://t.co/g1ouSE7er0 @APMA @ACFAS https://t.co/QHJryu4E76__
__1
__
- October 24, 2019
RT @SergylB : Diagnostic biomarkers and fluorescence imaging may have the potential to advance wound care - Venous News https://t.co/bELC1NxPMX__
__2
__
See more tweets
MOLECULIGHT HEADQUARTERS 425 University AvenueSuite 700
Toronto, ON M5G 1T6Canada
US Address
MolecuLight Corp.
2403 Sidney Street,
Suite 209
Pittsburgh, PA 15203T. +1 647-362-4684
North American Toll Free:1-877-818-4360
F. +1 647-362-4730
E: info@moleculight.comSITEMAP
* MolecuLight _I:X_
* Clinical Overview
* Case Studies
* Publications
* Posters
* Clinical Image Gallery * Training Resources * User Documentation* FAQ
* Executive Team
* Conferences & Events* Press Releases
* Contact Us
* Careers
MolecuLight is a proud corporate member of:ROW
2019 MolecuLight® Inc. All Rights Reserved. The MolecuLight _I:X_™ Imaging Device is approved by Health Canada and has CE marking for sale in Canada and the European Union. The MolecuLight _I:X_™ Imaging Device has received FDA clearance. MolecuLight® and Look to Heal® are registered trademarks in Canada,the US and the EU.
Privacy Policy
| Terms of Use
REFERENCES
* Wu YC, Smith M, Chu A, Lindvere-Teene L, Starr D, Tapang K, Wong O, Linden R, DaCosta RS. Handheld fluorescence imaging device detects subclinical wound infection in an asymptomatic patient with chronic diabetic foot ulcer: a case report. International Wound Journal, 2016, 13(4), 449-53. doi: 10.1111/iwj.12451. * DaCosta RS, Kulbatski I, Lindvere-Teene L, Starr D, Blackmore K, Silver JI, Opoku J, Wu YC, Medeiros PJ, Xu W, Xu L, Wilson BC, Rosen C, Linden R. Point-of-care autofluorescence imaging for real-time sampling and treatment guidance of bioburden in chronic wounds: first-in-human results. PLOS ONE, 2015, 10(2). doi: 10.1371/journal.pone.0116623. * Ottolino-Perry K, Chamma E, Blackmore KM, Lindvere-Teene L, Starr D, Tapang K, Rosen CF, Pitcher B, Panzarella T, Linden R, DaCosta RS. Improved detection of clinically relevant wound bacteria using autofluorescence image-guided sampling in diabetic foot ulcers. International Wound Journal, 2017, 14(5), 833-841. doi:10.1111/iwj.12717.
* Rennie MY, Lindvere-Teene L, Tapang K, Linden R. Point-of-care fluorescence imaging predicts the presence of pathogenic bacteria in wounds: a clinical study. Journal of Wound Care, 2017, 26(8), 452-460. doi: 10.12968/jowc.2017.26.8.452. * Raizman R. Point-of-care fluorescence imaging device guides care and patient education in obese patients with surgical site infections. Presented at CAWC 2016. Proceedings of the Annual Canadian Association of Wound Care Conference; 2016 Nov 3-6, Niagara Falls, ON, Canada. * Jeffery S. Utility of point-of-care autofluorescence imaging device in successful closure of major limb amputations – a case study. Presented at MHSRS 2016. Proceedings of the Military Health System Research Symposium; 2016 Aug 15-18; Kissimmee, FL, USA. * Dunham D, Teene L. Objective wound measurement software on a point-of-care, hand-held fluorescence imaging device: verification of measurement accuracy and repeatability. Presented at EWMA 2018. Proceedings of the Annual European Wound Management Association Conference; 2018 May 9-11; Krakow, Poland. * Wu YC, Kulbatski I, Medeiros PJ, Maeda A, Bu J, Xu L, Chen Y, DaCosta RS. Autofluorescence imaging device for real-time detection and tracking of pathogenic bacteria in a mouse skin wound model: preclinical feasibility studies. Journal of Biomedical Optics, 2014, 19(8). doi: 10.1117/1.JBO.19.8.085002. * Raizman R, DaCosta RS. Handheld real-time fluorescence imaging of bacteria guides treatment selection and timing of dressing changes in inpatients undergoing negative pressure wound therapy. Presented at IWH 2016. Proceedings of the Innovations in Wound Healing Conference; 2016 Dec 8-11, Key Largo, FL, USA. * Landis S, Rennie MY, Blumenthal E, Jeffery S. Use of fluorescence imaging in visualizing bacteria in chronic ulcers and traumatic soft tissue damage. Presented at AMSUS 2016. Proceedings of the Annual Meeting of the Society of Federal Health Professionals; 2016 Nov 29-Dec 2; National Harbor, MD, USA. * Landis S. Mapping venous ulcers using bacterial autofluorescence (BAF) to identify subgroups at risk of infection post debridement. Presented at CAWC 2016. Proceedings of the Annual Canadian Association of Wound Care Conference; 2016 Nov 3-6, Niagara Falls, ON, Canada. * Hill R, Douglas JJ. Effect of bacterial fluorescence imaging on patient care and wound management in a hospital setting: a pilot study. Presented at SAWC Spring 2017. Proceedings of the Annual Symposium on Advanced Wound Care; 2017 Apr 5-9; San Diego, CA, USA. * Hill R, Douglas JJ. Real-time bacterial fluorescence imaging guides antimicrobial stewardship in patients with diverse wounds. Presented at SAWC Spring 2017. Proceedings of the Annual Symposium on Advanced Wound Care; 2017 Apr 5-9; San Diego, CA, USA. * MolecuLight Inc. PN 1189 MolecuLight i:X User Manual. 2016. * Raizman R. Fluorescence imaging positively predicts bacterial presence and guides wound cleaning and patient education in a series of pilonidal sinus patients. Presented at Wounds UK 2016. Proceedings of the Annual Wounds UK Conference; 2016 Nov 14-16; Harrogate, UK.Cancel Continue
Request Quote Request Demo Request InfoDetails
Copyright © 2023 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0